H. Wan

Fosaprepitant versus aprepitant in the prevention of chemotherapy-induced nausea and vomiting in patients receiving cisplatin-based chemotherapy: a multicenter, randomized, double-blind, double-simulated, positive-controlled phase III trial

Jingdong He, K. Nan, Jian-hua Chang, 2020, Annals of translational medicine.

Randomized phase III trial of amrubicin/cisplatin versus etoposide/cisplatin as first-line treatment for extensive small-cell lung cancer

Ying Cheng, B. Han, He-long Zhang, 2016, BMC Cancer.

Biosimilar candidate IBI305 plus paclitaxel/carboplatin for the treatment of non-squamous non-small cell lung cancer.

Ying Cheng, Baolan Li, Yunpeng Liu, 2019, Translational lung cancer research.

[Differences in efficacy between drug-eluting beads transbronchial arterial chemoembolization combined with systemic chemotherapy and systemic chemotherapy alone for unresectable lung squamous cell carcinoma].

H. Wan, W. Li, J. Zhu, 2020, Zhonghua yi xue za zhi.

Randomized phase III trial of amrubicin/cisplatin versus etoposide/cisplatin as first-line treatment for extensive small-cell lung cancer

Ying Cheng, B. Han, He-long Zhang, 2016, BMC Cancer.